List of Excipients in Branded Drug VIAGRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
PFIZER LABORATORIES DIV PFIZER INC	VIAGRA	sildenafil citrate	0069-4200	ALUMINUM OXIDE
PFIZER LABORATORIES DIV PFIZER INC	VIAGRA	sildenafil citrate	0069-4200	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
PFIZER LABORATORIES DIV PFIZER INC	VIAGRA	sildenafil citrate	0069-4200	CELLULOSE, MICROCRYSTALLINE
PFIZER LABORATORIES DIV PFIZER INC	VIAGRA	sildenafil citrate	0069-4200	CROSCARMELLOSE SODIUM
PFIZER LABORATORIES DIV PFIZER INC	VIAGRA	sildenafil citrate	0069-4200	FD&C BLUE NO. 2
PFIZER LABORATORIES DIV PFIZER INC	VIAGRA	sildenafil citrate	0069-4200	HYPROMELLOSE
PFIZER LABORATORIES DIV PFIZER INC	VIAGRA	sildenafil citrate	0069-4200	LACTOSE

Viagra Excipient Strategy and Commercial Opportunities in Sildenafil Formulations

Last updated: August 26, 2026

Viagra’s commercial opportunity is no longer protected by meaningful brand exclusivity. The product is sildenafil citrate, an immediate-release film-coated tablet with a conventional excipient system: microcrystalline cellulose, dibasic calcium phosphate, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, triacetin, and FD&C Blue No. 2 aluminum lake. The strongest opportunities now lie in differentiated sildenafil products, including orally disintegrating tablets, rapid-dissolution formats, taste-masked products, lower-cost manufacturing platforms, and region-specific dosage forms.

The key commercial constraint is regulatory and clinical equivalence. A new product must preserve sildenafil exposure, dissolution performance, stability, dose uniformity, and patient acceptability while avoiding claims that create a new drug or combination-product regulatory burden.

What excipients are used in Viagra tablets?

Viagra tablets use a standard direct-compression or dry-granulation-compatible excipient platform. The inactive ingredients identified in the U.S. prescribing information are listed below.

Excipient	Primary function in Viagra
Microcrystalline cellulose	Filler, compression aid, tablet-bulk agent
Anhydrous dibasic calcium phosphate	Filler and compression aid
Croscarmellose sodium	Superdisintegrant
Magnesium stearate	Lubricant
Hypromellose	Film-coating polymer
Titanium dioxide	Opacifier and pigment
Triacetin	Plasticizer in the film coating
FD&C Blue No. 2 aluminum lake	Tablet-coloring agent

Viagra is supplied as blue, diamond-shaped, film-coated tablets in 25 mg, 50 mg, and 100 mg strengths. The formulation is designed for oral administration before sexual activity, with dose selection based on efficacy, tolerability, age, renal function, hepatic function, and interacting medicines. The product label states that sildenafil exposure is affected by food, particularly high-fat meals, which can delay absorption and reduce peak concentration.[1]

What does each excipient contribute to product performance?

The core tablet matrix balances mechanical strength and rapid breakup. Microcrystalline cellulose supports tablet hardness and manufacturability. Anhydrous dibasic calcium phosphate contributes density and compressibility but can increase tablet weight and may complicate some high-loading formulations.

Croscarmellose sodium drives tablet disintegration. Its performance depends on concentration, particle size, compaction force, and lubricant exposure. Excessive magnesium stearate or prolonged lubrication can reduce wetting and delay dissolution.

The film coating provides color, swallowability, surface protection, and brand recognition. Hypromellose and triacetin create the polymer-plasticizer system. Titanium dioxide and the aluminum lake provide opacity and blue coloration.

For generic and reformulated sildenafil products, the excipient system must be evaluated as a performance package. Substituting one filler or disintegrant may change hardness, friability, dissolution, stability, or bioequivalence outcomes.

What excipient strategy best supports sildenafil commercial products?

The strongest strategy is a platform approach rather than a direct copy of the Viagra formulation.

Immediate-release generic tablets

Conventional sildenafil tablets can use widely available compendial excipients with established regulatory histories. The commercial priorities are:

• Low-cost compression and coating.
• Rapid and consistent dissolution.
• Stable sildenafil citrate content.
• Low tablet weight.
• Robust manufacturing across multiple strengths.
• Acceptable appearance without dependence on the Viagra trade dress.

Anhydrous dibasic calcium phosphate and microcrystalline cellulose provide a practical filler system. Croscarmellose sodium remains a logical disintegrant for immediate-release products. Sodium starch glycolate or crospovidone can be considered as alternatives, but each may alter water uptake, tablet swelling, dissolution, and stability.

Orally disintegrating tablets

An orally disintegrating tablet could improve convenience for patients who have difficulty swallowing or prefer discreet administration. The most relevant excipient categories include:

• Mannitol or isomalt for mouthfeel and sweetness.
• Crospovidone or optimized croscarmellose sodium for rapid disintegration.
• Colloidal silicon dioxide for flow improvement.
• Flavor systems and high-intensity sweeteners.
• Taste-masking polymers or ion-exchange systems.
• Direct-compression binders optimized for low-force compaction.

Sildenafil has a bitter taste, so taste masking is a central technical issue. A successful ODT would need fast disintegration without releasing an unacceptable bitter bolus in the mouth. Taste masking can use polymer coating, complexation, adsorbent carriers, or multiparticulate approaches. Each method may affect dissolution and bioavailability.

Chewable and orally dispersible formats

Chewable sildenafil products may have consumer appeal but create greater taste and dose-uniformity challenges than swallowable tablets. Sugar alcohols can improve mouthfeel but may introduce hygroscopicity, gastrointestinal tolerability issues, and stability risks.

Orally dispersible granules or sachets could support flexible dosing and differentiated distribution. These products would require careful control of sildenafil content uniformity, moisture exposure, packaging, and reconstitution or dispersion behavior.

Fast-dissolving and rapid-onset claims

A formulation that dissolves faster in vitro does not automatically produce faster clinical onset. Sildenafil absorption remains affected by gastric emptying, food intake, dose, and patient-specific factors. A commercial claim based on faster onset would require clinical support and careful regulatory positioning.

The more defensible initial claim is often improved administration convenience rather than a broad superiority claim. A rapid-dissolution product can still have commercial value if it offers improved portability, easier administration, or less dependence on water.

What formulation patents protect sildenafil products?

The original Viagra intellectual-property position centered on sildenafil compounds, pharmaceutical compositions, and methods for treating erectile dysfunction. The foundational U.S. sildenafil patent, U.S. Patent No. 5,250,534, expired in 2012 after pediatric exclusivity was taken into account. Pfizer’s method-of-use patent U.S. Patent No. 6,469,012, associated with erectile-dysfunction treatment, expired later than the compound patent.[2][3]

The principal commercial consequence is that sildenafil tablets are now exposed to generic competition. Formulation developers cannot rely on the original Viagra formulation as a protected market. New patent opportunities would need to arise from genuinely novel and non-obvious subject matter, such as:

• A stable amorphous or co-crystal form.
• A novel taste-masking architecture.
• A specific ODT composition with demonstrated performance.
• A controlled-release or modified-release system.
• A formulation with a new pharmacokinetic profile.
• A manufacturing process that materially improves impurity control or yield.
• A fixed-dose combination with a non-obvious clinical or formulation benefit.

A simple substitution of one conventional filler for another is unlikely to create strong patent protection. Patent value is stronger when the excipient combination produces a measurable technical effect, such as improved stability under high humidity, faster disintegration at low compression force, reduced bitterness, or improved content uniformity.

What is the FDA and Orange Book status of Viagra?

Viagra was approved by the FDA under NDA 020895 on March 27, 1998. It is a prescription product containing sildenafil citrate for the treatment of erectile dysfunction.[1]

The original Orange Book exclusivity period and listed patents have expired. Sildenafil generic products received FDA approval through abbreviated new drug applications after the relevant exclusivity barriers ended. The FDA Orange Book remains the primary source for current patent and exclusivity listings, but expired patents do not block ordinary generic entry.[4]

Regulatory item	Status
Active ingredient	Sildenafil citrate
Reference product	Viagra
Original NDA	020895
Initial FDA approval	March 27, 1998
Dosage form	Immediate-release film-coated tablet
Strengths	25 mg, 50 mg, 100 mg
Exclusivity position	Expired
Generic pathway	ANDA
Biosimilar pathway	Not applicable
Current commercial barrier	Bioequivalence, quality, supply, branding, and distribution

Are Paragraph IV challenges relevant to Viagra?

Paragraph IV litigation was relevant during the transition from Pfizer’s protected market to generic sildenafil. Generic applicants can certify that a listed patent is invalid, unenforceable, or will not be infringed. A first Paragraph IV filing can trigger a 30-month stay under the Hatch-Waxman framework if the brand holder files timely patent litigation.[5]

For current sildenafil development, historic Paragraph IV disputes are less important than the remaining regulatory and commercial requirements. New litigation risk could arise if a company obtains later patents covering a specific formulation, dosage regimen, manufacturing method, or combination product and lists those patents in the Orange Book where legally permitted.

Which companies compete in the sildenafil market?

The market includes Pfizer’s Viagra brand, authorized or branded generic channels, and multiple generic manufacturers. The competitive field varies by country and by distributor. Generic sildenafil is generally sold under the active-ingredient name or manufacturer-specific brands.

Competition is based on:

• Wholesale acquisition cost.
• Pharmacy and payer access.
• Supply reliability.
• Tablet strengths and pack sizes.
• Telehealth distribution.
• Direct-to-consumer marketing.
• Packaging and discreet fulfillment.
• Regulatory status in each country.

For a new entrant, a standard 50 mg tablet is the most crowded segment. Differentiation is more plausible through a patient-use problem, such as swallowing difficulty, taste, portability, dose flexibility, or improved stability in hot and humid climates.

What commercial opportunities exist for sildenafil excipients?

Excipient suppliers can capture value through formulation platforms rather than individual commodity sales.

Co-processed excipients

Co-processed fillers and disintegrants can simplify manufacturing and improve flow, compaction, and tablet robustness. A supplier may position a platform for low-force direct compression or high-speed tableting. The commercial advantage must be demonstrated in sildenafil or a comparable low-dose, immediate-release model.

Taste-masking systems

Taste masking is the most promising excipient opportunity for ODT, chewable, and orally dispersible sildenafil products. Suppliers can offer polymer coatings, lipid barriers, ion-exchange complexes, or adsorbent technologies. The critical performance measures are bitterness reduction, rapid drug release after swallowing, stability, and manufacturability.

Moisture-control systems

Sildenafil formulations may require protection from moisture and temperature during manufacturing and storage. Low-moisture excipients, desiccant-compatible packaging, and high-barrier blister systems can reduce degradation and preserve dissolution. The commercial opportunity is strongest in markets with high humidity and weak cold-chain infrastructure, because sildenafil does not require refrigerated distribution.

Functional coating systems

Film-coating suppliers can offer lower-weight coatings, faster processing, improved color uniformity, and protection from light or moisture. A new color system can reduce dependence on the original Viagra appearance and simplify global regulatory compliance where colorants have different permitted uses.

How strong is the patent estate for new sildenafil excipient products?

A generic sildenafil tablet has limited freedom to build value through composition patents because the active ingredient and basic immediate-release use are established. The strongest protection is likely to come from a layered estate:

1. Composition-of-matter or solid-state claims, where available.
2. Specific excipient combinations.
3. Manufacturing-process claims.
4. Stability or impurity-control claims.
5. Dosage-form claims covering ODT, chewable, multiparticulate, or dispersible products.
6. Method-of-use claims tied to a distinct patient population or dosing protocol.
7. Trade dress, trademark, packaging, and distribution protections.

The patent estate should be paired with regulatory exclusivity only where the product qualifies. A new excipient combination used in a conventional sildenafil product generally does not create FDA exclusivity by itself. A genuinely new drug product may require a 505(b)(2) application rather than an ANDA, depending on the extent of formulation and clinical differentiation.[6]

What manufacturing and IP barriers affect sildenafil reformulation?

The main barriers are technical execution and regulatory proof.

Manufacturing barriers

Low-dose sildenafil formulations require tight content uniformity. Lubrication, segregation, particle-size differences, and electrostatic behavior can affect dose consistency. Taste-masked particles can segregate from larger excipient particles or damage during compression.

ODTs create a separate tradeoff between rapid disintegration and mechanical strength. High porosity improves breakup but can increase friability and moisture sensitivity. Packaging must protect the dosage form without creating excessive cost.

Intellectual-property barriers

A developer must review:

• Later patents covering ODT or taste-masked sildenafil.
• Patents on excipient-drug complexes.
• Process patents for particle engineering.
• Patents on combination therapies.
• Trademark and trade-dress restrictions.
• Country-specific patent rights and supplementary protection mechanisms.

Freedom-to-operate analysis must be jurisdiction-specific. U.S. expiry does not eliminate exposure in Europe, China, India, Brazil, or other markets where later patents may have different terms or validity outcomes.

What generic launch scenarios exist for Viagra alternatives?

Product strategy	Regulatory route	Commercial potential	Main risk
Conventional sildenafil tablet	ANDA	High volume, low margin	Heavy competition
ODT sildenafil	ANDA or 505(b)(2), depending on differences	Moderate to high	Taste and bioequivalence
Chewable sildenafil	Usually differentiated pathway	Moderate	Bitterness and patient acceptability
Sachet or dispersible granules	Product-specific	Moderate	Stability and dose uniformity
Combination product	505(b)(2) or new NDA	Potentially high	Clinical and IP complexity
Novel controlled-release product	505(b)(2) or new NDA	Niche	Pharmacokinetic and safety requirements

The most practical launch path is a conventional generic tablet supported by a second-generation ODT or dispersible product. This approach combines near-term volume with a differentiated follow-on product.

Key Takeaways

• Viagra contains a conventional immediate-release excipient system built around microcrystalline cellulose, dibasic calcium phosphate, croscarmellose sodium, magnesium stearate, and a hypromellose film coat.
• Original Viagra patent and exclusivity barriers have expired, leaving sildenafil open to generic competition.
• Standard sildenafil tablets are commercially crowded and usually compete on cost, supply, and distribution.
• ODT, taste-masked, chewable, and dispersible formats offer the clearest formulation-led opportunities.
• Strong new patent protection requires a measurable technical effect, not a routine excipient substitution.
• Excipient suppliers can create value through taste masking, co-processed direct-compression systems, moisture control, and functional coatings.
• Biosimilar risk is irrelevant because sildenafil is a small-molecule drug, not a biologic.
• A differentiated formulation may require a 505(b)(2) pathway rather than an ANDA.
• Geographic freedom to operate must be assessed separately because patent expiry and regulatory requirements differ by country.

FAQs

Can a new sildenafil tablet copy Viagra’s excipients?

A developer can use similar inactive ingredients if the formulation complies with regulatory requirements and does not infringe an unexpired patent. The product cannot use Pfizer trademarks, Viagra trade dress, or misleading branding.

Which excipient is most important for sildenafil ODT performance?

The disintegrant system is central, but taste masking is usually the decisive development issue. Crospovidone, croscarmellose sodium, mannitol, polymer coatings, and flavor systems must be optimized together.

Does a faster-dissolving sildenafil tablet act faster than Viagra?

Not necessarily. Faster in-vitro dissolution may not produce faster clinical onset because food, gastric emptying, and absorption determine systemic exposure. A faster-onset claim requires appropriate clinical evidence.

Can excipients create FDA exclusivity for a sildenafil product?

Excipients alone generally do not create exclusivity. A new formulation may qualify for patent protection and, depending on the product and regulatory pathway, regulatory protections associated with a new drug application.

Is sildenafil subject to biosimilar competition?

No. Sildenafil is a chemically synthesized small molecule. Competition occurs through generic-drug pathways, primarily ANDAs in the United States, rather than biosimilar applications.

References

1. U.S. Food and Drug Administration. (2024). Viagra prescribing information. Pfizer Laboratories. https://labeling.pfizer.com
2. U.S. Patent No. 5,250,534. (1993). Pyrazolopyrimidinone antianginal agents. United States Patent and Trademark Office.
3. U.S. Patent No. 6,469,012. (2002). Treatment of erectile dysfunction. United States Patent and Trademark Office.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
5. U.S. Food and Drug Administration. (2017). ANDA submissions: Refuse-to-receive standards. https://www.fda.gov
6. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/development-approval-process-drugs/505b2-applications.